Structure Therapeutics reports Q1 2023 net loss of $18.0M; GSBR-1290 advancing to Phase 2a

Structure Therapeutics Inc.

2023-Q1 EPS reported -$0.25

Net loss of $18.0M for Q1 2023, compared to $13.1M in Q1 2022; non-cash stock-based comp $2.5M.
Cash, cash equivalents and short-term investments totaled $240.9M; expected to fund operations through end of 2025.
R&D expenses $13.1M (up from $8.5M) driven by GLP-1R franchise advancement and stock-based compensation.
GSBR-1290 protocol amendment submitted to FDA to transition to Phase 2a proof-of-concept study in T2DM and obesity.
Topline data from Phase 1b MAD and Phase 2a studies of GSBR-1290 expected in second half 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Structure Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $18.0 million.

Period: the first quarter ended March 31, 2023
Net income: $18.0 million
Result: reported results

Exact text from the filing

Net loss totaled $18.0 million for the first quarter of 2023

View on SEC.gov

Browse all earnings releases →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-059189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.